TreeFrog Therapeutics Awarded the Galien MedStartup Prize 2020 for its International Consortium on iPSC Quality with US, Japan & France October 28, 2021
TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan September 13, 2021
Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality June 21, 2021
C-Stem™ outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells May 11, 2021
World first: TreeFrog Therapeutics announces the production of a single batch of 15 billion iPS cells in a 10L bioreactor with exponential amplification of 276-fold per week. April 12, 2021
The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants November 17, 2020
